New drug cocktail aims to fight stomach cancer when first treatment fails
NCT ID NCT07139587
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has worsened or who could not tolerate first-line treatment. The goal is to see if this combination can shrink tumors and extend survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab/Tuvonralimab (immunotherapy) combined with albumin-bound paclitaxel (chemotherapy)
What this could lead to
If successful, this could offer a new second-line treatment option for advanced stomach cancer, potentially extending life and controlling the disease.
What could go wrong
This is a very small, early-phase trial with only 30 participants. The combination may not work better than existing options and could cause significant side effects from both immunotherapy and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei General Hospital
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact